ProCE Banner Activity

Phase II ALTER1202: Randomized Trial of Anlotinib for SCLC in the Third-line Setting and Beyond

Slideset Download
Conference Coverage
In this phase II study, the multitargeted TKI anlotinib appeared to provide significant PFS and DCR benefit for patients with SCLC who progressed after 2 lines of chemotherapy.

Released: October 02, 2018

Expiration: October 01, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants

AbbVie

AstraZeneca

Genentech TEXT Only

Takeda Oncology